Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Gross Profit | -10,000 | 16.7% |
| Cost of Revenue | 10,000 | 16.7% |
| Operating expense | 3.9M | 3.8% |
| Net Income | -3.6M | 2.2% |
| EBITDA | -3.6M | 2.3% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 82M | 146.8% |
| Total Liabilities | 3.5M | 27.5% |
| Total Equity | 78M | 157.7% |
| Shares Outstanding | 48M | 31.8% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -3.8M | 49.3% |
| Cash from investing | -45M | 3315.7% |
| Cash from financing | 51M | 976.9% |
EPS
Financial Highlights for Microbot Medical in Q3 '25
Gross Profit stood at -10,000, marking a 16.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 10,000, a -16.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.9M, showing a 3.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -3.6M, showing a -2.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -3.6M, showing a -2.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Microbot Medical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
